Intra-operative Pancreatoscopy in Patients With IPMN
Active, not recruiting · NCT03729453
Conditions: Intraductal Papillary Mucinous Neoplasm
At a glance
- Research payments reported, 2025
- $33,777
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 100
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- SpyGlass (device)
- Dates
- Started 2019-03-20; completion 2027-05
- Results posted
- Not yet
To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.
From ClinicalTrials.gov, last updated 2026-07-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $33,777 in research payments for this study in 2025 (14 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Marco Del Chiaro, MD Surgical Oncology · Aurora, CO
- Christian M. Schmidt, MD General Surgery · Indianapolis, IN
- Richard Burkhart Surgical Oncology · Baltimore, MD
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Indiana University $17,146
- Johns Hopkins University $14,124
- Regents of the University of Colorado $2,507
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.